Literature DB >> 15226367

The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation.

Emanuela Napoleone1, Angelomaria di Santo, Giuseppe Peri, Alberto Mantovani, Giovanni de Gaetano, Maria Benedetta Donati, Roberto Lorenzet.   

Abstract

Pentraxin-3 (PTX3), an acute-phase protein that belongs to the family of the PTXs, is found elevated in septic shock and increased in patients with acute myocardial infarction. As tissue factor (TF) plays a key role in thrombosis and inflammation associated with atherosclerosis and as we have recently reported that PTX3 increases TF synthesis in endothelial cells, we tested whether PTX3 could modulate TF expression in monocytes. Monocytes from peripheral blood of healthy donors were incubated with highly purified PTX3 with or without lipopolysaccharide (LPS). Cells were then disrupted, and procoagulant activity was assessed by a one-stage clotting time. PTX3 enhanced TF activity and antigen from LPS-stimulated monocytes in a dose-dependent way. The effect was specific, as other PTXs, such as C-reactive protein and serum amyloid P component, were ineffective. Moreover, the increase in activity was specific for LPS, as in the presence of other TF-inducing agents such as interleukin-1beta and tumor necrosis factor alpha, PTX3 was not effective. The increase in TF activity requires mRNA synthesis, as assessed by polymerase chain reaction. The mechanism by which PTX3 modulates TF synthesis resides in an enhanced IkappaB, alpha phosphorylation and degradation and increased migration of the transacting factor c-Rel/p65 into the nucleus, as determined by Western blot and electro-mobility shift assay. These results show that PTX3 is an enhancer of the expression of TF by mononuclear cells. In the area of vascular injury, during the inflammatory response, cell-mediated fibrin deposition takes place. PTX3 increases TF expression, thus potentially playing a role in thrombogenesis and wound healing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15226367     DOI: 10.1189/jlb.1003528

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  39 in total

1.  Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury.

Authors:  Bing Han; Jack J Haitsma; Yu Zhang; Xiaohui Bai; Matthew Rubacha; Shaf Keshavjee; Haibo Zhang; Mingyao Liu
Journal:  Intensive Care Med       Date:  2010-11-12       Impact factor: 17.440

Review 2.  Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules.

Authors:  Martin Wolley; Meg Jardine; Colin A Hutchison
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-05       Impact factor: 8.237

3.  Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.

Authors:  Tommaso Mauri; Giacomo Bellani; Nicolo' Patroniti; Andrea Coppadoro; Giuseppe Peri; Ivan Cuccovillo; Massimo Cugno; Gaetano Iapichino; Luciano Gattinoni; Antonio Pesenti; Alberto Mantovani
Journal:  Intensive Care Med       Date:  2010-01-30       Impact factor: 17.440

4.  Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile.

Authors:  Michela Zanetti; Alessandra Bosutti; Clara Ferreira; Pierandrea Vinci; Gianni Biolo; Maurizio Fonda; Matteo Valente; Luigi Cattin; Gianfranco Guarnieri; Rocco Barazzoni
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

5.  PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation.

Authors:  Xiaolin He; Bing Han; Xiaohui Bai; Yu Zhang; Marcelo Cypel; Marco Mura; Shaf Keshavjee; Mingyao Liu
Journal:  Intensive Care Med       Date:  2009-11-18       Impact factor: 17.440

6.  C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood.

Authors:  A Landsem; E W Nielsen; H Fure; D Christiansen; J K Ludviksen; J D Lambris; B Østerud; T E Mollnes; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

7.  Severe Acinetobacter baumannii sepsis is associated with elevation of pentraxin 3.

Authors:  Patrick M Ketter; M Neal Guentzel; Beverly Schaffer; Maryanne Herzig; Xiaowu Wu; Robbie K Montgomery; Bijaya K Parida; Chriselda G Fedyk; Jieh-Juen Yu; James Jorgensen; James P Chambers; Andrew P Cap; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

Review 8.  Pentraxins, anti-pentraxin antibodies, and atherosclerosis.

Authors:  N Bassi; S Zampieri; A Ghirardello; M Tonon; M Zen; F Cozzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

9.  The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood.

Authors:  A Landsem; H Fure; D Christiansen; E W Nielsen; B Østerud; T E Mollnes; O L Brekke
Journal:  Clin Exp Immunol       Date:  2015-08-02       Impact factor: 4.330

Review 10.  Pattern recognition by pentraxins.

Authors:  Alok Agrawal; Prem Prakash Singh; Barbara Bottazzi; Cecilia Garlanda; Alberto Mantovani
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.